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38 The Journal of Thoracic and Cardiobjectives: Some investigators have reported long-term survival after surgical
esection of a solitary non–small cell lung cancer recurrence in various sites.
owever, the role and indications of the second operation remain unclear.
ethods: We reviewed 28 patients with a solitary recurrence after successful initial
esection of primary non–small cell lung cancer who underwent resection of the
ecurrent lesion. The clinicopathologic factors associated with outcome were ana-
yzed.
esults: There were 17 men and 11 women. Recurrence resection was performed for
he following sites: 16 in the lung, 5 in the brain, 2 in the adrenal gland, and 1 each
n the chest wall, stomach, skin, pelvic lymph node, and malar bone. The median
urvival time was 25 months, and the 1-, 2-, and 5-year survival rates after
ecurrence were 89%, 59%, and 32%, respectively. Advanced p-stage (p-stage II
nd III, n 14) of the primary tumor was the significant negative prognostic factor.
atients with p-stage II or III had survival equivalent to that of those who had
ultiple recurrences or were unfit for further surgical intervention.
onclusions: Resection of a solitary non–small cell lung cancer recurrence might
rovide long-term survival in highly selected patients. However, surgical resection
ight be contraindicated if the primary tumor is stage II or III.
ive-year survival rates of patients with non–small cell lung cancer (NSCLC)
have been disappointing, even after successful complete resection, with about
50% of patients eventually experiencing recurrence and death from the
isease.1 Recurrent lesions are generally multiple and disseminated, and additional
urgical intervention is usually not indicated. Some investigators have reported
ong-term survivals after solitary recurrence resection of the brain, adrenal gland,
pleen, liver, and bone.2-10 However, the role and indication of surgical intervention
emain unclear. The aim of this study is to investigate clinicopathologic character-
stics of patients with NSCLC who underwent resection of a solitary recurrent lesion
nd to identify prognostic factors.
atients and Methods
atients
e retrospectively reviewed the clinical and pathologic files of 1698 consecutive patients
ith NSCLC who had undergone complete surgical resection at the National Cancer Center
ospital East from 1989 through 2002. Data collection and analyses were approved, and the
eed for obtaining informed consent from each patient was waived by the institutional review
oard in January 2004. Patients with synchronous metastasis (M1) were excluded. Among
hem, we identified 592 (35%) patients with locoregional or distant recurrence in 2003 or
arlier. We excluded patients with second pulmonary lesions that were not clearly distin-
uished from metachronous second primary NSCLC on the basis of the criteria of Martini and
elamed.11 Our follow-up procedures included physical examination, chest roentgenogra-
vascular Surgery ● April 2006
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TShy, and blood testing, including tumor markers, 1 month after the
nitial operation, every 3 to 6 months during the first 3 years, and
very half year to 1 year thereafter. If any abnormality was found,
e performed computed tomographic scans. We did not routinely
erform bone scanning and brain examinations for asymptomatic
atients. When a lesion suggesting locoregional or distant recur-
ence was detected, we scrutinized the whole body radiologically.
Thirty of the 592 patients underwent resection of a solitary
ecurrent lesion. Among them, 2 patients who had recurrence-free
ntervals (RFIs) of 1 and 4 months, respectively, were eliminated
rom this study because they possibly had undetectable “missed”
1 disease at the initial operation. Nine of the 28 patients were
ymptomatic at the time of recurrence detection. All but 1 patient,
ho had intrapulmonary recurrence, were asymptomatic. The me-
ian period from recurrence detection to the second operation
as 2.6 months (range, 0.2-24 months). The follow-up protocols
ere the same before and after recurrence resection. The median
ollow-up period after recurrence resection was 33 months, rang-
ng from 11 to 128 months.
For the remaining 562 patients, surgical intervention was not
ndicated because recurrences were multiple, patients were unfit
or further surgical intervention, or both. They underwent pallia-
ive chemotherapy, radiotherapy, or best supportive care. Patients
ith multiple recurrences who underwent palliative operations for
ymptomatic sites were included in this group.
rognostic Evaluation
e attempted to identify prognostic factors associated with sub-
equent survival after resection of a solitary recurrent lesion. We
valuated the following factors: clinical characteristics at recur-
ence (sex, age, carcinoembryonic antigen level, time from initial
esection to recurrence detection [RFI], symptoms at the time of
ecurrence, site of recurrence, and mode of recurrence [locore-
ional or distant]) and pathologic findings of the primary lung
ancer (histology, tumor size, lymph node status, p-stage, and
ymphatic and vascular permeations). We defined locoregional
ecurrence as recurrence within the ipsilateral thorax and distant
ecurrence as all other recurrences. Each pathologic specimen was
eviewed by a board-certified pathologist who was blinded to the
linical outcome. Histology was specified on the basis of the
orld Health Organization classification for cell types.12 Patho-
ogic stages were determined on the basis of the TNM classifica-
ion of the International Union Against Cancer.13
urvival Analysis
urvivals were calculated by using the Kaplan-Meier method and
ere compared with the log-rank test. Zero time was the date of
ecurrence identification, and the terminal event was defined as
Abbreviations and Acronyms
FDG  18F fluorodeoxyglucose
NSCLC non–small cell lung cancer
PET  positron emission tomography
RFI  recurrence-free intervaleath from any cause. An observation was censored at the last l
The Journal of Thoracicollow-up when the patient was alive or lost to follow-up. Factors
ith a P value of less than .15 were entered into the multivariate
nalysis by using the Cox proportional hazards stepwise model.
ll statistical analyses were performed with a software package
JMP, release 5.0; SAS Institute Inc, Cary, NC).
esults
atient Characteristics
linicopathologic characteristics of 28 patients who under-
ent resection of a solitary recurrent lesion are shown in
able 1. There were 17 men and 11 women, with a median
ge of 65 years (range, 39-73 years) at the time of resection
f the recurrent lesion. At the initial operation, 26 of 28
atients underwent lobectomy and systemic mediastinal
ABLE 1. Clinicopathologic characteristics of 28 patients
ith NSCLC who underwent resection of a solitary
ecurrent lesion
haracteristics Value No.
linical characteristics at
recurrence
Age at recurrence
resection (y)
Median 65
Range 39-73
Sex Male 17
Female 11
RFI (mo) Median 23
Range 6-82
CEA level (ng/mL) Median 3.5
Range 0.5-3286
Recurrent site Ipsilateral lung 8
Contralateral lung 8
Brain 5
Adrenal grand 2
Chest wall 1
Stomach 1
Skin 1
Abdominal lymph node 1
Bone (malar bone) 1
athologic characteristics of
primary tumor
Histology Adenocarcinoma 21
Squamous cell
carcinoma
5
Adenosquamous
carcinoma
1
Pleomorphic carcinoma 1
Size of primary tumor (cm) Mean  SD 4.1  1.7
p-Stage of primary tumor IA/IB 4/10
IIA/IIB 2/6
IIIA/IIIB 4/2
Nodal status of primary
tumor
N0/N1/N2 18/7/3
FI, Recurrence-free interval; CEA, carcinoembryonic antigen; SD, stan-
ard deviation.ymph node dissection. Two patients underwent limited
and Cardiovascular Surgery ● Volume 131, Number 4 839
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G
TSung resection because of insufficient pulmonary reserve.
eoadjuvant platinum-based chemotherapy was adminis-
ered to 1 patient because of clinical N2 status. All patients
chieved macroscopically complete surgical removal of
heir primary NSCLC tumor, but the resection margin was
athologically positive in 1 patient. The patient had recur-
ence in the adrenal gland. RFI was almost 2 years (median,
3 months; range, 6-82 months). The lung (n  16) was the
ost frequent site of recurrence. The mode of resection for
ntrapulmonary recurrences included 3 completion pneumo-
ectomies, 1 lobectomy, and 12 limited resections. Distal
astrectomy was performed for the patient who had gastric
ecurrence with severe progressive anemia, and open lymph
ode resection was performed for the patient with pelvic
ymph node recurrence. Complete removal of the recurrence
as accomplished in all patients. There was no complica-
ion after resection of the recurrent lesion. One of 5 patients
ith brain recurrence received whole-brain irradiation post-
peratively. No patients underwent systemic chemotherapy
fter resection of the recurrent lesion.
urvival and Prognostic Factors After Resection of the
olitary Recurrent Lesion
igure 1 shows comparative survival curves after recurrence
mong 28 patients who underwent resection of the solitary
ecurrent lesion and 562 patients in whom an additional
peration was not indicated. Overall 1-, 2-, and 5-year
igure 1. Comparative survival curves among 28 resected pa-
ients and 562 patients without resection. The difference in sur-
ival probability after recurrence is significant (1-, 2-, and 5-year
urvivals after recurrence: 89%, 59%, and 32% vs 46%, 26%, and
%; P < .001).urvivals after recurrence were significantly better in pa- N
40 The Journal of Thoracic and Cardiovascular Surgery ● Apriients who underwent resection of a solitary recurrent lesion
han in those who did not undergo resection (89%, 59%, and
2% vs 46%, 26%, and 6%; P .001). The median survival
imes after recurrence were 25 and 11 months, respectively.
Table 2 shows the relationship between survival after
esection of the recurrent lesion and the clinicopathologic
haracteristics of the 28 patients. Multivariate analysis dem-
nstrated that advanced p-stage (stage II-III) of the primary
ung cancer was the significant negative prognostic factor
ssociated with survival after recurrence detection (hazard
atio, 6.15; 95% confidential interval, 1.09-30.8; P  .04).
s shown in Figure 2, the patients with p-stage II or III
isease demonstrated survival statistically equivalent to that
f patients not undergoing resection after recurrence detec-
ion (P  .11). In 14 patients with p-stage I disease, 10 and
patients survived for more than 2 and 5 years, respec-
ively, after recurrence detection. One with recurrence in the
alar bone is surviving for 7 years without a distant failure.
n contrast, 3 and 1 of 14 patients with p-stage II or III
isease survived for more than 2 and 5 years, respectively,
ut with a distant failure.
iscussion
ost recurrences after primary NSCLC resection are mul-
iple and disseminated and are usually treated with systemic
hemotherapy when patients can tolerate it. Although many
tudies have shown that systemic chemotherapy prolongs
urvival in unresectable stage IV NSCLC, there have been
o large-scale, randomized prospective trials addressing
hether chemotherapy improves survival of patients with
ecurrence.14 In an effort to improve long-term tumor con-
rol and subsequent survival, attempts have been made to
ncorporate surgical intervention in selected cases of soli-
ary NSCLC recurrence. Evidence that a solitary recurrent
esion can be effectively treated with surgical intervention
xists for malignancies other than lung cancer. For colorec-
al cancer, melanoma, and thyroid cancer, resection of re-
urrent lesions can offer prolonged survival.15-17 For lung
ancer, some investigators have reported acceptable sur-
ival after resection of the recurrent lesion, but others have
ontradicted these conclusions. Abrahams and coworkers4
emonstrated a satisfactory outcome in brain recurrence,
ith a median survival time of 18 months and a 5-year
urvival rate of 28.9%. In contrast, Saitoh and associates2
onducted 24 brain resections, with a 5-year survival rate of
nly 8.3%. Prognostic factors for survival after resection of
he recurrent lesion have not been clarified.
Although our patient population was heterogeneous, with
variety of recurrence sites, the overall survival after re-
ection of the recurrent lesion was acceptable by current
tandards, with a median survival time of 25 months and a
-year survival rate of 32%. The patients with a solitary
SCLC recurrence arising from an advanced primary tumor
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TSith p-stage II or III disease, however, had a poor outcome
quivalent to that seen in patients with recurrent NSCLC in
hom surgical intervention was not indicated. This suggests
hat advanced stage (ie, II or III) in the primary tumor is a
ontraindication for surgical intervention in patients with a
olitary recurrence. Consistent with our result, Yoshino and
oworkers18 described a strong relationship between patho-
ogic stage and clinical courses after recurrence in patients
ith NSCLC. They reported that the mean postrecurrent
urvival time was 590 days in pathologic stage I disease,
81 days in stage II disease, 257 days in stage IIIA disease,
nd 180 days in stage IIIB disease, with a significant dif-
erence being observed between stages I and IIIA (P 
0215). In patients with advanced and biologically aggres-
ive NSCLC, a solitary recurrence might be just the begin-
ing of progressive-disseminated disease.
In our series patients who underwent resection of the
ntrapulmonary recurrent lesion showed slightly but not
ignificantly better survival than the extrapulmonary recur-
aracteristics and survival after resection of a solitary
2-y survival (%) 5-y survival (%)
Univariate
analysis,
P value
Multivariate
analysis,
P value
43 26 .41 —
75 38
53 31 .48 —
67 33
68 45 .25 —
51 22
30 Not reached .13 .80
70 38
53 18 .33 —
60 36
71 40 .15 .50
42 21
57 46 .41 —
61 23
55 31 .73 —
67 33
51 17 .18 —
66 47
67 40 .08 .40
41 14
76 51 .0045 .04
10 10
44 Not reached .32 —
67 33
57 29 .97 —
61 36
nic antigen; Ad, adenocarcinoma; Ly, lymphatic permeation; V, vascularigure 2. Comparative survival curves among 14 resected pa-
ients with p-stage II or III primary non–small cell lung cancer
nd 562 patients without resection. There is no significant differ-ABLE 2. Relationship between patient clinicopathologic ch
ecurrent lesion
Factors No.
MST
(mo)
ge at recurrence resection (y) 65 14 22
65 14 27
ex Male 17 26
Female 11 28
FI (y) 2 13 26
2 15 27
EA level at recurrence (ng/mL) 5 9 22
5 19 30
ymptoms at recurrence  9 26
 19 28
ite of recurrence Intrapulmonary 16 30
Extrapulmonary 12 22
ode of recurrence Locoregional 10 26
Distant 18 27
istology Ad 21 26
Non-Ad 7 30
ize of primary tumor (cm) 4 14 26
4 14 28
odal status of primary tumor N0 (N) 18 30
N1/N2 (N) 10 22
-Stage of primary tumor I 14 —
II/III 14 19
y in primary tumor  10 21
 18 27
in primary tumor  17 27
 11 26
ST, Median survival time; RFI, recurrence-free interval; CEA, carcinoembryoence group (P  .15). This might be because some in-
and Cardiovascular Surgery ● Volume 131, Number 4 841
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G
TSrapulmonary lesions were actually metachronous second
rimary lung cancers. We can expect better prognosis for
etachronous lung cancer compared with intrapulmonary
ecurrence.19,20 It can often be hard to discriminate a soli-
ary pulmonary recurrence from a metachronous second
rimary lung cancer if the 2 lesions are of the same histo-
ogic type.21 Therefore aggressive surgical resection for an
ntrapulmonary lesion might be justified for patients with
dequate pulmonary reserve, regardless of the primary tu-
or pathology.
Although we did not perform positron emission tomog-
aphy (PET) with 18F fluorodeoxyglucose (FDG) for the
atients in this study, FDG-PET has been reported to be a
elpful adjunct in screening for distant metastases but not
or brain metastases.22 Several investigators have reported
hat FDG-PET could detect unexpected metastatic lesions in
0% to 20% of patients with newly diagnosed NSCLC.23,24
ET imaging might also be helpful in avoiding surgical
ntervention in patients who have multiple recurrent le-
ions.25 However, it is well known that FDG is not tumor
pecific and is also taken up in benign lseions.22 Lardinois
nd colleagues26 have reported that 46% of solitary ex-
rapulmonary lesions detected by means of integrated PET
nd computed tomography were unrelated to lung cancer
etastases. Further studies will be needed to clarify whether
ET imaging is useful in identifying more clearly the pop-
lation that benefits from additional surgical intervention
nd in prolonging subsequent survival.
The limitation of the current study is that the number of
nrolled patients, especially in the surgical resection group,
as obviously small. Therefore a multi-institutional study
ould be required to confirm our findings.
In conclusion, long-term survival can be achieved by
eans of resection of a solitary recurrent lesion in highly
elected patients. However, surgical resection might be con-
raindicated if the primary NSCLC stage is II or III, espe-
ially when the recurrent lesion is extrapulmonary.
We thank Professor J. Patrick Barron, International Medical
ommunications Center, Tokyo Medical University, for reviewing
he English-language manuscript.
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